This post hoc analysis of an 18-week randomized trial explored the utility of calculating baseline glycated haemoglobin (HbA1c), postprandial glucose (PPG) increments and nocturnal glucose change in predicting efficacy and safety outcomes in response to bolus insulin intensification in people with type 2 diabetes (T2D). Analyses were conducted on 236 participants with T2D receiving metformin: 116 received fastacting insulin aspart (faster aspart) basal-bolus therapy and 120 received basal-only insulin. Participants were grouped according to baseline HbA1c, PPG increments and nocturnal glucose change variables; analyses were performed on the end-of-trial treatment differences between "high" and "low" baseline values. The change from baseline in end-of-trial mean HbA1c and mean PPG increments was in favour of faster aspart across all subgroups. Significantly greater treatment differences were observed in participants with high (vs. low) baseline nocturnal glucose change and PPG increments. For baseline HbA1c, significantly greater treatment differences were observed for change in end-of-trial PPG increments, but not end-of-trial HbA1c. In conclusion, both nocturnal glucose change and PPG increments may be more useful than HbA1c for identifying subgroups of people with T2D who would most benefit from bolus intensification. 
| INTRODUCTION
In people with type 2 diabetes (T2D), suboptimal glycaemic control increases the risk of developing micro-and macrovascular complications. 1 For non-pregnant adults, current guidelines recommend a glycated haemoglobin (HbA1c) target of <53 mmol/mol (7.0%). 2 When patients do not achieve glycaemic targets using a combination of lifestyle modifications and oral antidiabetic drugs, treatment can be intensified with basal insulin, 2 but this alone is not always effective. 3 As HbA1c approaches 53 mmol/mol (7.0%), postprandial glucose (PPG), rather than fasting plasma glucose, becomes the dominant contributor to overall HbA1c, and many people require further treatment intensification with drugs targeting PPG excursions (eg, mealtime bolus insulin). 2, 4, 5 In routine clinical practice, it is difficult to identify, in a timely manner, the people with T2D who would most likely benefit from intensification with bolus insulin, 6 which may result in the uptitration of basal insulin, increasing risk of weight gain and hypoglycaemia. 7 Characteristics related to severity of disease, such as elevated HbA1c and self-measured blood glucose (SMBG)-derived PPG increments, are associated with suboptimal glycaemic control in people with T2D and have been shown to predict the HbA1c-lowering effect of insulin therapy. 5, 8, 9 However, HbA1c does not provide an indication of short-term glycaemic control, and measuring PPG increments can be time-consuming and disrupt patients' lives. 10 The change in nocturnal blood glucose from bedtime to pre-breakfast (termed herein as "nocturnal glucose change") is an SMBG-derived measure that only requires two blood glucose readings; it is easier and quicker to calculate than PPG increments and, when elevated, indicates a need to target PPG. 11 Moreover, calculating baseline nocturnal glucose change may provide a simple method for identifying patients who would benefit most from bolus insulin intensification.
To evaluate the value of calculating baseline nocturnal glucose change compared with PPG increments, existing clinical trial data were used. This post hoc analysis explored the utility of HbA1c, PPG increments and nocturnal glucose change, all at baseline, in predicting efficacy and safety outcomes in participants who intensified basal insulin treatment with mealtime faster aspart.
| METHODS
The present study was a post hoc analysis of the onset 3 trial been previously reported. 12 The trial design and inclusion criteria are summarized in Figure S1 and Appendix S1. Baseline characteristics were well matched across both treatments (Table S1 and Appendix S1). All participants were included in the post hoc analysis.
| Post hoc analysis population and outcomes
In this post hoc analysis, we explored the predictive utility of baseline glycaemic variables (HbA1c, PPG increments and nocturnal glucose change) on clinical outcomes in T2D. Clinical outcomes included in this analysis were change from baseline in HbA1c and mean PPG increments at the visit 18 weeks post-randomization and the rates of treatment-emergent severe or blood glucose-confirmed hypoglycaemia. "Treatment-emergent" was defined as an event that
had an onset up to 1 day after the last day of randomized treatment, but excluded any events that occurred during the run-in period.
Severe or blood glucose-confirmed hypoglycaemic episodes were defined with a plasma glucose value <3.1 mmol/L (56.0 mg/dL), with or without symptoms consistent with severe hypoglycaemia.
To explore the predictive utility of baseline HbA1c, PPG increments and nocturnal glucose change, analyses were performed on the treatment outcome differences (faster aspart basal-bolus minus basal-only therapy) at week 18, comparing "high" and "low" baseline values of each variable. "High" and "low" were defined as being above or below the median value at baseline, respectively. The median values for each variable at baseline were: 61.7 mmol/mol (7.8%) for HbA1c; 2.42 mmol/L (43.6 mg/dL) for PPG increment; and 3.11 mmol/L (56 mg/dL) for nocturnal glucose change. The correlation between these variables at baseline was also investigated.
The PPG increments were calculated as the difference between SMBG readings 2 hours post-meal and pre-meal, and these were recorded from seven-point profiles over a 3-day period, and averaged over time. Nocturnal glucose change was calculated as the difference between SMBG at bedtime and pre-breakfast the following day. From seven-point SMBG profiles over a 3-day period, two values could be calculated with a complete dataset, which were averaged to calculate mean nocturnal glucose change.
Definitions of the analysis sets, and details of the statistical models and tests, are provided in Appendix S1. 
| Association between baseline characteristics and end-of-trial HbA1c and PPG
Changes in HbA1c and mean PPG increment from baseline to week 18, stratified by baseline variables, are shown in Figures 1 and   2 , respectively. Treatment differences in these outcomes were consistently in favour of faster aspart basal-bolus therapy versus basal-only therapy in all of the "high" and "low" baseline subgroups. There were statistically significantly greater treatment differences in change in HbA1c in participants with "high" baseline nocturnal glucose change (P = 0.0006) and PPG increment (P = 0.0099) than in those with "low"
values. There was no statistically significant treatment difference in change in HbA1c (P = 0.533) between participants with "high" and "low" baseline HbA1c values (Figure 1 ). Statistically significantly greater treatment differences in the change from baseline in mean PPG increment were present in participants with "high" baseline HbA1c (P = 0.0007) , nocturnal glucose change (P < 0.0001) and PPG increment (P = 0.0141) than those with "low" baseline values (Figure 2 ).
| Association between baseline characteristics and hypoglycaemic episodes
Overall, there were higher absolute rates of severe or blood glucoseconfirmed hypoglycaemia in those participants receiving faster aspart basal-bolus therapy versus basal-only therapy ( Figure S2 ). The absolute rates of hypoglycaemia were numerically greater in both treatment arms in those with "high" versus "low" baseline HbA1c, PPG increment and nocturnal glucose change values; however, there were no statistically significant differences in treatment rate ratios of severe or blood glucose-confirmed hypoglycaemia between the "high"
and "low" baseline subgroups ( Figure S2 ). In addition to monitoring HbA1c, healthcare professionals should consider measuring nocturnal glucose change and/or PPG increment In conclusion, in the present trial population, the analysis suggests that PPG increment and nocturnal glucose change measurements may be more useful predictors than HbA1c for identifying people with T2D on basal insulin therapy, with or without oral antidiabetic drugs, who would most benefit from intensification with bolus insulin. Further, nocturnal glucose change may indeed perform just as well as PPG increment, while being easier to measure. The clinical applicability and potential use of nocturnal glucose change as a predictor for insulin intensification in T2D warrants further exploration.
| DISCUSSION
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